Bergauer, Lisa
Braun, Julia
Roche, Tadzio Raoul
Meybohm, Patrick
Hottenrott, Sebastian
Zacharowski, Kai
Raimann, Florian Jürgen
Rivas, Eva
López-Baamonde, Manuel
Ganter, Michael Thomas
Nöthiger, Christoph Beat
Spahn, Donat R.
Tscholl, David Werner
Akbas, Samira
Article History
Received: 12 July 2022
Accepted: 6 April 2023
First Online: 11 April 2023
Competing interests
: DRS’ academic department is receiving grant support from the Swiss National Science Foundation, Berne, Switzerland, the Swiss Society of Anesthesiology and Perioperative Medicine (SSAPM), Berne, Switzerland, the Swiss Foundation for Anesthesia Research, Zurich, Switzerland, Vifor SA, Villars-sur-Glâne, Switzerland and Vifor (International) AG, St. Gallen, Switzerland. DRS is co-chair of the ABC-Trauma Faculty, sponsored by unrestricted educational grants from Novo Nordisk Health Care AG, Zurich, Switzerland, CSL Behring GmbH, Marburg, Germany, LFB Biomédicaments, Courtaboeuf Cedex, France and Octapharma AG, Lachen, Switzerland. DRS received honoraria / travel support for consulting or lecturing from: Danube University of Krems, Austria, European Society of Anesthesiology and Intensive Care, Brussels, BE, Korean Society for Patient Blood Management, Seoul, Korea, Korean Society of Anesthesiologists, Seoul, Korea, Network for the Advancement of Patient Blood Management, Haemostasis and Thrombosis, Paris, France, Alexion Pharmaceuticals Inc., Boston, MA, Bayer AG, Zürich, Switzerland, B. Braun Melsungen AG, Melsungen, Germany, CSL Behring GmbH, Hattersheim am Main, Germany and Berne, Switzerland, Celgene International II Sàrl, Couvet, Switzerland, Daiichi Sankyo AG, Thalwil, Switzerland, Haemonetics, Braintree, MA, USA, Instrumentation Laboratory (Werfen), Bedford, MA, USA, LFB Biomédicaments, Courtaboeuf Cedex, France, Merck Sharp & Dohme, Kenilworth, New Jersey, USA, Novo Nordisk Health Care AG, Zurich, Switzerland, PAION Deutschland GmbH, Aachen, Germany, Pharmacosmos A/S, Holbaek, Denmark, Pfizer AG, Zürich, Switzerland, Pierre Fabre Pharma, Alschwil, Switzerland, Portola Schweiz GmbH, Aarau, Switzerland, Roche Diagnostics International Ltd, Reinach, Switzerland, Sarstedt AG & Co., Sevelen, Switzerland and Nümbrecht, Germany, Shire Switzerland GmbH, Zug, Switzerland, Tem International GmbH, Munich, Germany, Vifor Pharma, Munich, Germany, Neuilly sur Seine, France and Villars-sur-Glâne, Switzerland, Vifor (International) AG, St. Gallen, Switzerland, Zuellig Pharma Holdings, Singapore, Singapore. DWT and CBN are designated inventors of Visual-Patient-avatar technology, for which the University of Zurich holds various patents and trademarks. There are cooperation and licensing agreements with Philips Medizin Systeme Böblingen GmbH, Böblingen, Germany; Koninklijke Philips NV, Amsterdam, The Netherlands; Philips Research/Philips Electronics Nederland BV, Eindhoven, The Netherlands, Philips North America, Cambridge, MA, USA. Under these agreements, DWT receives grant support, and DWT and CBN receive travel support and may receive royalties. DWT, CBN, and DRS are designated inventors of Visual Clot technology, for which the University of Zurich holds various patents and trademarks. The University of Zurich signed a letter of intent for a cooperation and licensing agreement with Instrumentation Laboratory Company/Werfen Corporation, Bedford, MA, USA and Barcelona, Spain. Under resulting agreements, they may receive royalties. DWT, CBN, and DRS received travel support for consulting Instrumentation Laboratory, Bedford, MA, USA. DWT received honoraria and travel support from the Swiss Foundation for Anesthesia Research, Zurich, Switzerland. PM and/or the Department received research grants from the German Research Foundation (ME 3559/1-1, ME 3559/3-1), BMBF (01KG1815), BMG (ZMVI1-2520DAT10E), International Anesthesia Research Society, German Society of Anaesthesiology and Intensive Care Medicine, European Society of Anaesthesiology, grants by B. Braun Melsungen, CSL Behring, Fresenius Kabi and Vifor Pharma for the implementation of Frankfurt’s Patient Blood Management Program; by Pfizer and Dr. F. Köhler Chemie GmbH for investigator-initiated trial; honoraria for scientific lectures from Abbott GmbH &Co KG, Aesculap Academy, B.Braun Melsungen, Biotest AG, Vifor Pharma, Ferring, CSL Behring, German Red Cross/Institute of Transfusion Medicine, HCCM Consulting GmbH, Heinen&Löwenstein, Hemosonics, Pharmacosmos, Siemens Healthcare; prices from Aktionsbündnis Patientensicherheit (APS), European Society of Anaesthesiology (ESA), Lohfert-Stiftung AG, Masimo—Patient Safety Foundation, MSD-Gesundheitspreis. KZ has received honoraria for participation in advisory board meetings for Haemonetics and Vifor and received speaker fees from CSL Behring and GE Healthcare. He is the Principal Investigator of the EU-Horizon 2020 project ENVISION (Intelligent plug-and-play digital tool for real-time surveillance of COVID-19 patients and smart decision-making in Intensive Care Units) and Horizon Europe 2021 project COVend (Biomarker and AI-supported FX06 therapy to prevent progression from mild and moderate to severe stages of COVID-19). All other authors have no competing interests to declare.